RT @PhylFerrell: It has never been a more exciting time for #Alzheimers research, but #clinicaltrial recruitment still takes too long. Do y….

The #Alzheimers drug development pipeline has never been more promising, writes @PhylFerrell. To seize this opportunity to advance innovation and help patients, we must ensure #ClinicalTrials are speedy, representative and robust.

Trying to figure out your own risk from wildfire smoke exposure can be overwhelming, Schaeffer Sr. Scholar Wandi Bruine de Bruin told the @latimes. She recommends focusing on the most relevant data & shifting focus to simple steps to limit future exposure.

RT @WisconsinADRC: How much does it cost to live with dementia? @USCAgingCog's Dr. Julie Zissimopoulos joins #DementiaMatters to discuss th….

As the Trump Administration considers most-favored nation pricing, the US should confront foreign countries’ discriminatory use of QALY-based drug pricing & ensure such practices aren’t imported here, Schaeffer Scholars wrote in formal comments.

"Although the IRA introduced sweeping changes intended to ease the burden on older Americans, insurers’ strategic responses may end up shifting costs in new and unpredictable ways," writes @ConsumerAffairs on new Schaeffer Center research.

Health insurers this week pledged to ease the burden of #PriorAuthorization, potentially reducing red tape and speeding up access to care. USC Schaeffer research shows how use of pre-treatment approvals has grown significantly in Medicare Part D.

A troubling disconnect has emerged in America’s fight against #diabetes, Schaeffer's Jack Chapel writes. While the risks of health complications for people w/diabetes have significantly improved since the 90s, their labor market outcomes haven’t budged.

“When you start cutting staff, there are going to be some shortcuts taken,” Schaeffer Sr. Scholar @ProfGenKanter told @statnews @LizzyLaw_. “You’re going to have less time to search for qualified experts. You may not have as much experience in defining what the market is.”.

Our new white paper finds Part D plans are shifting more costs onto #Medicare beneficiaries as they adjust to the IRA’s new out-of-pocket cap. While the cap provides important protection, most beneficiaries won't reach the $2,000 annual limit.

Potential pharmaceutical tariffs could hit generic drugmakers especially hard — their average net profit margins are already much lower than those of brand-name firms, according to USC Schaeffer research cited in the @WSJ.

Stuck with a big hospital bill? Your hospital likely offers an interest-free payment plan, finds research by Schaeffer Scholar Erin Duffy cited in The Guardian.

USC's Clinical Trial Recruitment Lab, our partnership with @ATRI_USC, recently convened 40 leading experts to address an urgent question: How do we accelerate recruitment of a more representative population in #Alzheimers trials?. The key takeaways ⬇️

If RFK Jr. wants to “clean up the corruption and conflicts” at HHS, he is going about it the wrong way, writes Senior Scholar @ProfGenKanter in @statnews.

Schaeffer's @ProfGenKanter discusses w/@Reuters her upcoming research finding that declared conflicts of interest on CDC's vaccine advisory panel had declined significantly in recent years.

Medicare’s Coverage with Evidence Development program was meant to speed patient access to innovative treatments, but it’s instead become an unnecessary hurdle in need of major reform, Sr. Scholar @RealJoeGrogan writes in the @WSJ.

"The more you see how #PBMs have evolved and the games they play, the more you just get pessimistic that this little piecemeal legislation at the state level is going to do anything to them," said #USCSchaeffer Senior Scholar Geoffrey Joyce.

"Upcoding" patient diagnoses led to an estimated $50 billion in #MedicareAdvantage overpayments last year. Schaeffer Scholars Paul Ginsburg and Steve Lieberman in @Health_Affairs Forefront detail a two-part strategy for reining in the practice.

California hospital spending on supplemental payments to contracted medical groups has steadily grown in key specialties over the past two decades, Schaeffer Scholar Erin Duffy finds in a @Health_Affairs study.

New Schaeffer Center white paper finds targeted tax policies like tariffs or R&D credits do little to stimulate biomedical innovation. Instead, reducing corporate tax rates is key to supporting U.S. leadership in this critical area.